Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DX9LHC
|
||||
Drug Name |
4-azido-N-(2-(4-(4-chloro-2-fluorophenylamino)-6-methoxyquinazolin-7-yloxy)ethyl)-2,3,5,6-tetrafluorobenzamide
|
||||
Synonyms |
CHEMBL382716
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C24H15ClF5N7O3
|
||||
Canonical SMILES |
COc1cc2c(Nc3ccc(Cl)cc3F)ncnc2cc1OCCNC(=O)c4c(F)c(F)c(N=[N+]=[N-])c(F)c4F
|
||||
InChI |
InChI=1S/C24H15ClF5N7O3/c1-39-15-7-11-14(33-9-34-23(11)35-13-3-2-10(25)6-12(13)26)8-16(15)40-5-4-32-24(38)17-18(27)20(29)22(36-37-31)21(30)19(17)28/h2-3,6-9H,4-5H2,1H3,(H,32,38)(H,33,34,35)
|
||||
InChIKey |
OUUWSKRYOAESIE-UHFFFAOYSA-N
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
HIF-1 signaling pathway | |||||
Transcriptional misregulation in cancer | |||||
Rheumatoid arthritis | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
S1P3 pathway | |||||
VEGFR1 specific signals | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.